Differences in IgG Fc Glycosylation are Associated with Outcome of Pediatric Meningococcal Sepsis by de Haan N et al.
Differences in IgG Fc Glycosylation Are Associated with
Outcome of Pediatric Meningococcal Sepsis
Noortje de Haan,a Navin P. Boeddha,b,c Ebru Ekinci,c Karli R. Reiding,a Marieke Emonts,d,e,f Jan A. Hazelzet,g
Manfred Wuhrer,a Gertjan J. Driessenc,h
aCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
bIntensive Care and Department of Pediatric Surgery, Erasmus MC, Sophia Children’s Hospital, University
Medical Center Rotterdam, Rotterdam, The Netherlands
cDivision of Pediatric Infectious Diseases & Immunology, Department of Pediatrics, Erasmus MC-Sophia
Children’s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands
dInstitute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
eDepartment of Paediatric Immunology, Infectious Diseases & Allergy, Great North Children’s Hospital,
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
fNIHR Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Trust and
Newcastle University, Newcastle upon Tyne, United Kingdom
gDepartment of Public Health, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
hDepartment of Paediatrics, Juliana Children’s Hospital/Haga Teaching Hospital, The Hague, The Netherlands
ABSTRACT Pediatric meningococcal sepsis often results in morbidity and/or death, es-
pecially in young children. Our understanding of the reasons why young children are
more susceptible to both the meningococcal infection itself and a more fulminant
course of the disease is limited. Immunoglobulin G (IgG) is involved in the adaptive im-
mune response against meningococcal infections, and its effector functions are highly
influenced by the glycan structure attached to the fragment crystallizable (Fc) region. It
was hypothesized that IgG Fc glycosylation might be related to the susceptibility and se-
verity of meningococcal sepsis. Because of this, the differences in IgG Fc glycosylation
between 60 pediatric meningococcal sepsis patients admitted to the pediatric intensive
care unit and 46 age-matched healthy controls were investigated, employing liquid
chromatography with mass spectrometric detection of tryptic IgG glycopeptides. In addi-
tion, Fc glycosylation profiles were compared between patients with a severe outcome
(death or the need for amputation) and a nonsevere outcome. Meningococcal sepsis pa-
tients under the age of 4 years showed lower IgG1 fucosylation and higher IgG1 bisec-
tion than age-matched healthy controls. This might be a direct effect of the disease;
however, it can also be a reflection of previous immunologic challenges and/or a higher
susceptibility of these children to develop meningococcal sepsis. Within the young pa-
tient group, levels of IgG1 hybrid-type glycans and IgG2/3 sialylation per galactose were
associated with illness severity and severe outcome. Future studies in larger groups
should explore whether IgG Fc glycosylation could be a reliable predictor for meningo-
coccal sepsis outcome.
IMPORTANCE Meningococcal sepsis causes significant mortality and morbidity
worldwide, especially in young children. Identification of risk factors for a more ful-
minant infection would help to decide on appropriate treatment strategies for the
individual patients. Immunoglobulin G (IgG) plays an essential role in humoral im-
mune responses and is involved in the adaptive immune response against meningo-
coccal infections. Of great influence on the receptor affinity of IgG is the N-glycan
on its fragment crystallizable (Fc) portion. In the present study, we analyzed IgG gly-
cosylation during the fast development of meningococcal sepsis in children, and we
were able to identify glycosylation features that are different between meningococ-
cal sepsis patients and healthy controls. These features might be indicative of a
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higher susceptibility to meningococcal sepsis. In addition, we found glycosylation
features in the patients that were associated with illness severity and severe disease
outcome, having the potential to serve as a disease outcome predictor.
KEYWORDS children, critical care, Fc glycosylation, immunoglobulin G,
meningococcal sepsis, N-glycan, outcome
Meningococcal infections continue to cause significant mortality and morbidity,despite important reductions in the number of cases as a result of vaccination
programs (1, 2). Several factors associated with susceptibility and/or severity have been
identified, e.g., living in crowded conditions, passive smoking and antecedent viral
infections (3, 4). In addition, younger age (4 years) is an important risk factor for both
disease susceptibility and severity, presumably due to an immature immune system (1,
5, 6). However, the exact mechanism causing young children to be more vulnerable and
the factors determining the course of disease are largely unknown (5). Besides identi-
fying risk factors for the susceptibility of children to be admitted to the pediatric
intensive care unit (PICU) with meningococcal sepsis, there is a great interest in
identifying prognostic markers to predict the course of the disease and severe out-
comes (e.g., death or the need for amputation). These markers would help to decide on
appropriate treatment strategies for the individual patients (7). Several laboratory
markers have proven to be of predictive value for the course of meningococcal sepsis,
including levels of procalcitonin, C-reactive protein (CRP), leukocytes, thrombocytes,
plasminogen activator inhibitor 1 (PAI-1), fibrinogen, and various cytokines (8–10). In
addition to the individual markers, predictive scores were developed and validated for
the course of meningococcal sepsis, among which the pediatric risk of mortality (PRISM)
score (11), the Rotterdam score (9), and the base rate and platelet count (BEP) score
(12). These scores were all reported to have a good predictive performance for
meningococcal sepsis mortality with an area under the concentration-time curve (AUC)
between 0.80 and 0.96 (12).
Immunoglobulin G (IgG) plays an essential role in humoral immune responses and
is highly involved in the adaptive immune response against meningococcal infections
(13, 14). IgG specific for meningococcal serogroup B is able to initiate complement-
dependent lysis of the bacterium and leukocyte-mediated phagocytosis (15, 16). Both
the complement- and the leukocyte-mediated effector functions are mainly induced by
IgG1 and IgG3, while the other two IgG subclasses show less activity (IgG2) or no
activity at all (IgG4) (14). It was suggested that the severity of the disease in young
children in particular is not determined by the abundance of (certain subclasses of)
antimeningococcal IgG, but rather by either the specificity or affinity of the IgG
molecule for the antigen or the IgG receptors (13).
Of great influence on the receptor affinity of IgG is the N-glycan on its fragment
crystallizable (Fc) at Asn297 (17, 18). The Fc portion of the IgG molecule is
N-glycosylated in the endoplasmic reticulum (ER) and Golgi apparatus of B lympho-
cytes, a process that is under the regulation of both genetic factors and environmental
B cell stimuli (19–21). Functional studies have shown the effect of alterations in IgG Fc
glycosylation on the binding affinity to both Fc receptors (FcR) and complement
factor C1q (22). For example, increased IgG1 Fc galactosylation showed increased C1q
binding and complement-dependent cytotoxicity (CDC) (22, 23). Of note, afucosylation
of IgG1 Fc glycans resulted in substantially increased binding of the antibody to FcRIIIa
and FcRIIIb, which resulted in increased antibody-dependent cellular cytotoxicity
(ADCC) (18, 22).
In addition to the influence of IgG Fc glycosylation on receptor interaction, changes
in the glycosylation are also associated with various inflammatory diseases, like active
tuberculosis infections (24), HIV (25), alloimmune cytopenias (26, 27), and autoimmune
diseases like rheumatoid arthritis (28) and inflammatory bowel disease (29, 30). Because
of the large influence of IgG glycosylation on antibody function and its association with
inflammatory processes, we hypothesize that the fast development of meningococcal
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sepsis could be associated with Fc glycosylation profiles in the total plasma IgG pool.
The aim of this study was to identify differences in IgG Fc glycosylation between
pediatric meningococcal sepsis patients and age-matched healthy controls. In addition,
we evaluated the potential of specific glycosylation features to serve as a predictive
marker for disease outcome.
RESULTS
IgG Fc glycosylation was analyzed in a subclass-specific way for 60 pediatric patients
with a meningococcal infection admitted to the PICU, as well as for 46 age- and
sex-matched healthy controls (Table 1; see Table S1 in the supplemental material). For
all samples, 22 IgG1 Fc glycoforms were quantified, for 57 cases and 34 controls, 15
IgG2/3 glycoforms were quantified, and for 48 cases and 29 controls, 10 IgG4 glyco-
forms were quantified (Fig. 1; see Tables S1 and S2 in the supplemental material). From
these directly measured glycan traits, derived traits were calculated per IgG subclass.
This was done based on glycan type (complex or hybrid-type), bisection, fucosylation,
galactosylation, and sialylation (Table 2 and Table S2). The samples of the healthy
controls, remeasured in the present study, were a subset of a larger cohort previously
analyzed using a different technique, based on the matrix-assisted laser desorption
ionization–time-of-flight mass spectrometry (MALDI-TOF MS) detection of derivatized
glycopeptides (31). The healthy controls featured a lower IgG1 fucosylation and IgG1
and IgG2/3 sialylation with higher age, as already previously reported for this control
cohort (see Fig. S1 and Table S3 in the supplemental material). In addition, we detected
a lower relative abundance of IgG1 and IgG2/3 hybrid-type glycans with higher age in
the healthy controls, as well as a higher abundance of bisected glycans on IgG2/3 with
TABLE 1 Baseline characteristics of children admitted to the PICU with meningococcal
sepsis and of their age-matched healthy controlsa
Parameter
Result for patients or controls:
All <4 yr old >4 yr old
Patients
n 60 37 22
Age, yr (IQR) 2.5 (1.5–8.8) 1.8 (1.2–2.4) 10.1 (6.7–12.3)
Sex, male, n (%) 35 (59) 23 (62) 12 (55)
Illness severity
PRISM score (IQR) 20 (12–25) 21 (14–25) 19 (9–27)
P (death Rotterdam) 11 (1–82) 32 (2–89) 5 (1–14)
DIC score (IQR) 5 (4–6) 5 (4–7) 5 (4–7)
Coagulation markers
Thrombocytes, 106/liter (IQR) 97 (54–150) 92 (49–166) 109 (82–138)
Fibrinogen, g/liter (IQR) 2.3 (0.9–3.2) 2.3 (0.9–4.0) 2.2 (1.1–2.9)
PAI-1, g/ml (IQR) 4.8 (2.7–6.9) 5.4 (3.6–10.7) 4.3 (1.5–6.0)
Inflammatory markers
Leukocytes, 109/liter (IQR) 7.8 (4.0–15.3) 7.1 (3.4–14.3) 11.0 (5.5–17.2)
CRP, mg/liter (IQR) 74 (44–119) 60 (39–115) 91 (69–128)
Procalcitonin, ng/ml (IQR) 281 (83–482) 361 (145–498) 243 (20–468)
TNF-, pg/ml (IQR) 8.4 (5.0–19.8) 12.0 (5.3–23.0) 5.0 (5.0–17.5)
IL-6, ng/ml (IQR) 72 (18–383) 176 (42–723) 38 (1–258)
IL-8, ng/ml (IQR) 20 (4–119) 33 (5–219) 9 (1–58)
Outcome
Mortality, n (%) 12 (20) 10 (27) 2 (9)
Amputation, n (%) 7 (12) 2 (5) 5 (23)
Severe, n (%) 19 (32) 12 (32) 7 (32)
Controls
n 46 24 22
Age, yr (IQR) 3.9 (1.4–10.0) 1.5 (0.8–2.8) 10.0 (6.7–11.6)
Sex, male, n (%) 28 (61) 15 (63) 13 (59)
aMedians and interquartile ranges are presented, unless indicated differently. PRISM, pediatric risk of
mortality (11); P (death Rotterdam): predicted death rate based on the Rotterdam score (9); DIC,
disseminated intravascular coagulation (50), PAI-1, plasminogen activator inhibitor-1; TNF-, tumor necrosis
factor alpha. The number of samples for which specific clinical data were available can be found in
Table S1.
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higher age, both not previously described for healthy children in this age category
(Fig. S1) (31, 32).
IgG Fc glycosylation differences between patients with meningococcal sepsis
and healthy controls. Comparison of the derived glycosylation traits for all IgG
FIG 1 IgG1 glycoforms detected in healthy controls and meningococcal patients. (A and B) Representative mass spectra of a healthy 2.8-year-old boy (A) and
a 2.8-year-old male meningococcal patient (B). Annotated are the 15 overall most abundant IgG1 glycoforms; the glycoforms that were found to be higher
in the meningococcal patients compared to healthy controls (diantennary glycans without fucose or with a bisecting GlcNAc) are indicated in the spectrum
of the patient (B). The proposed glycan structures are based on fragmentation and literature (20, 31). Green circles, mannose; yellow circles, galactose; blue
squares, N-acetylglucosamine (GlcNAc); red triangles, fucose; pink diamonds, N-acetylneuraminic acid (Neu5Ac). a.u., arbitrary units.
TABLE 2 Derived glycosylation traitsa
Derived trait Depiction Description
Hybrid-type Fraction of hybrid-type glycans
Bisection Fraction of glycans with a bisecting N-acetylglucosamine
Fucosylation Fraction of glycans with a core fucose
Galactosylation Galactosylation per antenna of diantennary glycans
Sialylation Sialylation per antenna of diantennary glycans
Sialylation per
galactose
Sialylation per galactose of diantennary glycans
aThe individual glycoforms were grouped based on their glycosylation features as described before for IgG
glycopeptides (31). Green circles, mannose; yellow circles, galactose; blue squares, N-acetylglucosamine; red
triangles, fucose; pink diamonds, N-acetylneuraminic acid. The depictions of the derived traits show the
minimally required composition to contribute to the given trait. For detailed calculations of the traits, see
Table S2.
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subclasses between the meningococcal patients and the healthy controls (see Ta-
ble S4 in the supplemental material) revealed a lower IgG1 fucosylation in the children
with a meningococcal infection (median cases, 96.1%; controls, 97.8%) (Fig. 2A). When
comparing children in the younger age category (4 years old) separately from the
older children (4 years old), this effect appeared to be strongly present in the younger
children (cases, 96.1%; controls, 98.1%) (Fig. 2B and Table 3), while for the older children
the difference in IgG1 fucosylation was only detected as a trend (Fig. 2C). Also IgG1
bisection was shown to associate with disease in children below 4, being higher in
meningococcal patients (11.0%) than in healthy controls (8.4%) (Fig. 2E and Table 3). In
the older age group, a corresponding trend was observed (Fig. 2D and F).
IgG Fc glycosylation associates with patient outcome in children below 4 years
old. IgG Fc glycosylation differences between cases and controls were most pro-
nounced in the young children (below the age of 4 years), a group known to behave
FIG 2 IgG1 Fc fucosylation and bisection are different between meningococcal patients (M) and healthy
controls (H) below the age of 4 years. IgG1 Fc fucosylation in meningococcal patients between 0 and 18
(A), 0 and 3.9 (B), and 4 and 18 (C) years old compared to age-matched healthy controls and IgG1 Fc
bisection in meningococcal patients between 0 and 18 (D), 0 and 3.9 (E), and 4 and 18 (F) years old
compared to age-matched healthy controls. Shown are box and whisker plots, where the boxes
represent the interquartile range (IQR) and the whiskers 1.5 IQR. After multiple-testing correction,
P values below 2.7 103 were considered statistically significant (indicated by an asterisk). The number
of samples for which subclass-specific glycosylation data were available can be found in Table S1.
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clinically differently from older meningococcus-infected patients (5, 33). The glycosyl-
ation differences between patients with severe disease outcome (death or amputation)
and nonsevere disease outcome (full recovery) were only compared within this group
(Table 3), as our cohort contained high data density in this age category (see Fig. S2 in
the supplemental material). The abundance of hybrid-type structures on IgG1 was
found to be overall low (below 1%); however, it appeared to be even lower in patients
with a severe disease outcome (0.37%) compared to the patients that fully recovered
(0.50%) (Fig. 3A). A similar observation was done for the hybrid-type structures on
IgG2/3 (Fig. 3B), of which the levels correlated significantly with the levels of IgG1
hybrid-type glycans (see Fig. S3 in the supplemental material). In addition, IgG2/3
sialylation per galactose was lower in patients with a severe disease outcome (19.3%)
compared to the patients with nonsevere outcome (21.9%) (Fig. 3D). A similar trend
was also observed for sialylation per galactose on the other IgG subclasses (Fig. 3C and
E), which correlated positively with the levels on IgG2/3 (Fig. S3). The IgG1 hybrid-type
glycans and the sialylation per galactose on IgG2/3 associated negatively with the
Rotterdam score (IgG1 hybrid-type correlation coefficient [r]  0.6; IgG2/3 sialylation
per galactose, r  0.7 [Fig. 4; see Table S5 in the supplemental material]), known to
be predictive for patient outcome (9). Also IgG1 and IgG2/3 sialylation associated
negatively with the Rotterdam score (IgG1, r  0.5; IgG2/3, r  0.6). In addition,
IgG2/3 sialylation and IgG4 sialylation per galactose associated negatively with the
other clinically used predictive score, PRISM (r  0.6 for both [Fig. 4]) (11), which
correlated positively with the Rotterdam score (Fig. S3). The described associations
were less pronounced in the total data set and were not present for the older pediatric
patients (Fig. S3).
Associations between IgG Fc glycosylation and inflammatory markers. Various
inflammatory markers were measured in the patient samples, including levels of
thrombocytes, fibrinogen, PAI-1, CRP, leukocytes, procalcitonin, tumor necrosis factor
alpha (TNF-), and interleukin-6 (IL-6) and -8. Thrombocyte levels associated positively
with IgG1 and IgG2/3 hybrid-type glycans in the young children (r  0.6 for the
TABLE 3 Glycosylation differences between pediatric meningococcal patients (0 to 4 years of age) and age- and sex-matched healthy
controls and between meningococcal patients with severe and nonsevere disease outcomesa
Derived trait
Cases and controls <4 yr old Meningococcal patients <4 yr old
Median % (IQR)
P value
Median % (IQR)
P valueHealthy controls Patients Nonsevere Severe
IgG1
Hybrid-type 0.45 (0.43–0.52) 0.45 (0.41–0.53) 8.0E01 0.50 (0.44–0.54) 0.37 (0.35–0.43) 2.1E03
Bisection 8.4 (7.4–10.3) 11.0 (9.2–12.9) 2.0E03 10.0 (9.1–11.8) 13.1 (11.6–14.3) 3.0E02
Fucosylation 98.1 (97.8–98.4) 96.1 (94.2–97.3) 1.9E06 96.4 (94.6–97.8) 94.5 (93.9–95.8) 2.7E02
Galactosylation 61.9 (56.7–63.6) 61.6 (58.4–63.3) 8.2E01 62.2 (59.1–63.4) 59.7 (56.9–62.1) 2.1E01
Sialylation 11.3 (10.1–12.8) 10.6 (9.7–11.9) 1.5E01 11.2 (10.3–11.9) 9.6 (9.2–10.4) 1.8E02
Sialylation per galactose 18.4 (17.7–19.7) 17.8 (16.9–18.7) 3.7E02 18.2 (17.5–19) 17.2 (15.9–17.6) 1.6E02
IgG2/3
Hybrid-type 0.43 (0.40–0.54) 0.39 (0.30–0.49) 9.5E02 0.43 (0.39–0.51) 0.30 (0.25–0.35) 4.8E03
Bisection 7.4 (6.3–8.1) 9.7 (8.8–11.2) 4.0E03 9.2 (8.5–10) 11.1 (9.2–11.6) 1.2E01
Fucosylation 98.4 (98.3–98.7) 97.7 (97.5–98.1) 5.7E03 97.8 (97.5–98.4) 97.5 (97.5–98) 4.6E01
Galactosylation 54.5 (46.7–58.1) 51.4 (49.2–53.6) 5.1E01 51.8 (49.3–54.4) 51.3 (49.8–52.6) 6.1E01
Sialylation 13.1 (9.3–14.3) 10.6 (9.7–11.7) 2.1E01 11.0 (10.5–11.9) 9.6 (9.4–10.3) 8.3E03
Sialylation per galactose 23.7 (21.4–24.7) 21.1 (19.5–22.6) 1.4E02 21.9 (20.5–23.1) 19.3 (18.5–20.9) 2.0E03
IgG4
Bisection 13.2 (10.6–14.5) 15.5 (13.5–16) 1.7E01 14.2 (12.4–15.8) 15.9 (15.7–16.1) 3.8E02
Galactosylation 51.6 (44.5–54.9) 54.5 (52.5–58.2) 7.0E02 55.8 (52.4–59.1) 53.7 (52.7–55.4) 4.5E01
Sialylation 14.1 (11.3–14.9) 13.6 (12.4–14.7) 8.5E01 14.4 (13.4–15.4) 12.5 (12.3–13) 2.3E02
Sialylation per galactose 26.5 (25.2–28.6) 24.9 (23–26.7) 1.5E01 25.7 (23.6–27.3) 22.9 (22.6–25.1) 2.7E02
aMann-Whitney U tests were performed to compare the groups. After multiple-testing correction, P values below 2.7  103 were considered statistically significant
(indicated in boldface). For detailed calculations of the traits, see Table S2. The numbers of samples for which subclass-specific glycosylation data were available can
be found in Table S1.
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hybrid-type glycans on both subclasses) (Fig. 4 and Table S5). The same effect was seen
for IgG1 hybrid-type glycans and fibrinogen levels (r  0.6). In addition, IgG2/3
sialylation per galactose correlated positively with fibrinogen and thrombocyte
levels (r  0.6 and 0.7, respectively). Furthermore, IgG2/3 sialylation associated
negatively with PAI-1 levels (r  0.7) and IgG1 fucosylation associated negatively
FIG 3 Levels of IgG Fc glycosylation features between meningococcal patients below the age of 4 years with severe (S) and nonsevere (NS)
disease outcomes. Shown are box and whisker plots of the levels of (A) IgG1 hybrid-type glycans, (B) IgG2/3 hybrid-type glycans, (C) IgG1
sialylation per galactose, (D) IgG2/3 sialylation per galactose, and (E) IgG4 sialylation per galactose, where the boxes represent the interquartile
range (IQR) and the whiskers 1.5 IQR. After multiple-testing correction, P values below 2.7  103 were considered statistically significant
(indicated by an asterisk). The number of samples for which subclass-specific glycosylation data were available can be found in Table S1.
FIG 4 Correlation between IgG Fc glycosylation and clinical variables for meningococcal patients
between 0 and 3.9 years old. The Spearman correlation coefficient is represented in red for a positive
correlation and in blue for a negative correlation between the derived glycan trait and the outcome
scores and inflammatory markers. Periods indicate P  0.05, and crosses indicate P  2.7  103 ( 
2.7  103, adjusted to allow an FDR of 5%).
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with IL-6 (r  0.7). In the older pediatric meningococcal patients, leukocyte levels
were positively associated with IgG1 and IgG2/3 hybrid-type structures (r  0.6 for
both subclasses), and patients with lower CRP levels had lower levels of IgG2/3
hybrid-type structures (r  0.7) (Fig. S3 and Table S5).
DISCUSSION
IgG Fc glycosylation in patients with meningococcal sepsis. Pediatric meningo-
coccal infections resulting in septic shock often occur in young and previously healthy
children (1). The reason why young children are more susceptible to this severe
infection and the factors that determine the outcome of disease are largely unknown
(5). In this study, we analyzed the IgG Fc glycosylation of children admitted to the PICU
with meningococcal sepsis. Changes in IgG Fc glycosylation are known to have a large
influence on the effector function of the antibody and are associated with various
inflammatory conditions (18, 22–24, 28).
We found IgG1 Fc fucosylation to be lower in patients than in age-matched healthy
controls. As previous research showed no sex-related IgG glycosylation effects in
healthy children between 3 months and 17 years (31), the boys and girls in the present
study were not assessed separately. The observed difference between cases and
controls was more pronounced in children below the age of 4 years. In addition, in
children of this age category, IgG1 Fc bisection was higher in patients than in controls.
Previous studies reported a different disease course and mortality rate in very young
children, showing the relevance of studying this patient group separately from older
pediatric meningococcal sepsis patients (1, 5). Additionally, we found that the cytokine
levels in our cohort tended to be higher in younger patients than that in the older ones.
This might be explained by a trend of higher illness severity in young patients and
consequently higher cytokine levels. During the maturation of the immune system,
when children start to produce their own IgG molecules, the Fc fucosylation is relatively
high compared to that in older children (above the age of 4 years), while the Fc
bisection is relatively low (31). In young children with meningococcal sepsis, a change
in the glycosylation of a disease-specific subset of their IgGs might be induced by the
meningococcal infection itself in an early stage of the disease. IgG glycosylation is able
to change quickly, as shown in patients experiencing acute systemic inflammation after
cardiac surgery, where part of the patients showed an increased antibody galactosy-
lation the first day after surgery (34). In addition, studies in mice showed that Fc
sialylation could be regulated dynamically, by the interplay of soluble sialyltransferases
and the accumulation of platelets providing CMP-sialic acid (35, 36). The fact that sialyl-
and galactosyltransferases are also circulating in the human plasma suggests that
glycosylation might be dynamically regulated in humans too (37).
Alternatively, low Fc fucosylation and high Fc bisection in young patients rather
reflect the extent of exposure to previous infections and subsequent adaptive immune
responses. Antigen-specific IgG Fc glycosylation was previously shown to differ sub-
stantially from the glycosylation of the total pool of IgG. For example, gp120-specific
IgG in HIV-infected patients displays significantly lower Fc fucosylation than the total
pool of IgG in the infected patients (25). Furthermore, in alloimmune cytopenias also
low levels of Fc fucosylation were observed in anti-HPA-1a and anti-RhD IgGs, com-
pared to the total IgG pool (26, 27). Low IgG1 Fc fucosylation (i.e., high afucosylation)
enhances binding of IgG to FcRIIIa and FcRIIIb 20- to 100-fold (22, 38), thereby
increasing ADCC (18, 22). The 2-fold higher abundance of afucosylated IgGs that we
observed for meningococcal sepsis patients might reflect the upregulation of antigen-
specific groups of IgG. For IgG specific for meningococcal outer membrane vesicle
(OMV) antigens obtained after OMV vaccination, no change in fucosylation was seen
over time (39). However, no comparison was made between total IgG before and after
vaccination, and glycosylation changes on antigen-specific IgG might be substantially
different between vaccinated and naturally infected individuals. We speculate that the
low IgG fucosylation observed in young meningococcal patients may reflect a history
of exposure to (viral) infections, or in a broader sense antigenic stimuli, resulting in the
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buildup of low-fucosylation IgG against the respective antigens, which manifests itself
in a shift of the total IgG pool toward lower fucosylation. Hence, the low fucosylation
may be a marker of a history of infections which may, e.g., reflect a certain proneness
to viral or other infectious diseases in these children.
Future studies should elucidate whether skewed IgG Fc glycosylation featuring low
fucosylation and high bisection can be identified on meningococcus-specific IgG and
whether the deviations from normal are induced by the meningococcal infection or
were already present in the children before infection.
IgG Fc glycosylation associates with illness severity. Young patients with severe
disease, defined by death or need for amputation, have a lower level of IgG1 hybrid-
type glycans and IgG2/3 sialylation per galactose when admitted to the PICU. In
addition, these glycosylation features correlate negatively with illness severity, as
measured by the Rotterdam score, as well as positively with previously determined
predictive factors in meningococcal sepsis, namely, levels of thrombocytes and fibrin-
ogen (9), which correlate negatively with severity. Thus, our data suggest that IgG1
hybrid-type glycans and IgG2/3 sialylation per galactose could be a predictor for
meningococcal sepsis severity.
Hybrid-type glycans are known to be present on human IgG-Fc in minor amounts,
and not much is known about their function (40, 41). We show here, for the first time,
that the level of hybrid-type glycans on both IgG1 and IgG2/3 correlates negatively with
age in healthy children. This is likely connected to maturation of the immune system as
hybrid-type glycans are precursors of the usually found complex-type glycans on IgG
and might originate from immature B cells.
In the young patients, IgG2/3 Fc sialylation seems to change independently from the
level of Fc galactosylation (serving as a substrate for sialylation), which is likely an effect
of the higher availability of sialyltransferase ST6Gal1 or the increased presence of the
substrate CMP-sialic acid, either inside the Golgi apparatus or outside the cell (35, 36,
42). IgG1 Fc sialylation is known to modulate antibody binding to C1q, and subsequent
CDC, either positively (22) or negatively (23). This discrepancy is suggested to be caused
by the spatial distribution of the monoclonal antibodies on the cell surface, which
depends on the monoclonal antibody studied.
Similar to the glycosylation differences observed between cases and controls, the
question is whether the low levels of hybrid-type glycans and sialylation per galactose
are emerging during the course of the disease (and are thus meningococcal sepsis
specific) or were already present on (a fraction of) the IgG Fc of patients appearing to
have a severe disease outcome. In both situations, the alterations can either be the
cause of the severe outcome or a bystander effect. In either situation, IgG Fc glycosyl-
ation features have the potential to be used to predict meningococcal sepsis outcome
in very young patients, which should be validated in larger study populations.
Interestingly, IgG1 fucosylation associated negatively with IL-6 levels in patients
below the age of 4 years, while previous studies in healthy adults showed a positive
correlation between IL-6 levels and fucosylation (43). IL-6 levels have been shown
before to be elevated with meningococcal sepsis and to have a potential role in
outcome prediction (44). Furthermore, none of the glycosylation features are associated
with levels of CRP in the young patients, while CRP in the healthy adult population does
associate with IgG Fc galactosylation (negatively) and Fc fucosylation (positively) (43).
Low CRP levels at the time of admission at the PICU are a known predictor of mortality
rate in meningococcal sepsis (9), indicating that the prediction based on CRP is
grounded on different mechanisms than the prediction based on glycosylation fea-
tures. This opens possibilities to combine these factors for an improved prediction tool.
Conclusion. We found IgG1 fucosylation and bisection to be associated with
meningococcal sepsis in children below the age of 4 years. Within these young patients,
we found IgG1 hybrid-type glycans and IgG2/3 sialylation per galactose correlated with
the severity of the disease. Further research is needed to determine whether the
observed glycosylation differences between patients and controls are a result of the
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meningococcal infection itself or rather associated with increased susceptibility to
meningococcal septic shock. Furthermore, glycosylation changes associated with illness
severity have the potential to be used as outcome predictors, which should be
validated in larger study populations.
MATERIALS AND METHODS
Patients and controls. In the current retrospective study, plasma or serum samples of prospective
cohorts of children with meningococcal sepsis were used. Samples were collected from patients recruited
for pediatric meningococcal sepsis studies (1988 to 2005) at the PICU of Erasmus MC-Sophia Children’s
Hospital (Rotterdam, The Netherlands) (9, 45–47). These studies were conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines. All individual meningococcal studies as well
as the present study were approved by the Ethical Committee of Erasmus MC (MEC-2015-497), and
written informed consent was obtained from parents or legal guardians.
Blood samples from 60 children with meningococcal sepsis were taken within 6 h after admission to
the PICU. All patients fulfilled internationally agreed criteria for sepsis (48). Most patients already received
antibiotic treatment at the moment of sampling and had a central venous catheter in situ. In addition,
treatment and medication assisting in resuscitation were generally given (such as fluids and inotropes).
Samples were processed on ice and were stored at 80°C until analysis. The sample types comprised a
variety of serum, citrate plasma, heparin plasma, and EDTA plasma. For several patients, multiple
materials taken at the same time point were available.
Plasma samples of 46 healthy controls, selected to be in the same age range as the patients, were
collected in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines (31, 49).
The collection of the samples was approved by the Ethical Committee of Erasmus MC (MEC-2005-137),
and written informed consent was obtained from parents or legal guardians.
Clinical data collection. Various clinical data were collected, illness severity was indicated by
Pediatric Risk of Mortality (PRISM) (11), predicted death based on the Rotterdam score (9), and the
disseminated intravascular coagulation (DIC) score (50). Coagulation (thrombocytes, fibrinogen, and
PAI-1) and inflammation (leukocytes, procalcitonin, CRP, tumor necrosis factor alpha [TNF-], interleukins
[IL-6 and -8]) markers were measured for clinical reasons or were obtained in previous meningococcal
sepsis studies (9, 45, 47). Patients were classified to have died if death occurred during the PICU stay. The
need for amputation and/or the occurrence of death during the PICU stay were together classified as a
severe disease outcome.
Chemicals. Disodium hydrogen phosphate dihydrate (Na2HPO4·2H2O), potassium dihydrogen phos-
phate (KH2PO4), NaCl, and trifluoroacetic acid were purchased from Merck (Darmstadt, Germany). Formic
acid, ammonium bicarbonate, and TPCK (tosylsulfonyl phenylalanyl chloromethyl ketone)-treated trypsin
from bovine pancreas were obtained from Sigma-Aldrich (Steinheim, Germany). Furthermore, high-
performance liquid chromatography (HPLC) SupraGradient acetonitrile (ACN) was obtained from Bio-
solve (Valkenswaard, The Netherlands), and ultrapure deionized water (MQ) was generated by the
Purelab Ultra, maintained at 18.2 M (Veolia Water Technologies Netherlands BV, Ede, The Netherlands).
Phosphate-buffered saline (PBS [pH 7.3]) was made in house, containing 5.7 g/liter Na2HPO4·2H2O,
0.5 g/liter KH2PO4, and 8.5 g/liter NaCl.
IgG isolation and glycopeptide preparation. The 98 clinical samples and 46 healthy control
samples were randomized in a 96-well plate format, together with 32 VisuCon pooled plasma
standards (Affinity BioLogicals, Inc., Ancaster, Ontario, Canada [8 per plate]) and 16 PBS blanks
(minimally 2 per plate). Randomization was performed in a supervised way, selecting an optimal
distribution of age, sex, and case/control ratio per plate. IgG was isolated using protein G affinity
beads (GE Healthcare, Uppsala, Sweden) as described previously (51). Briefly, 2 l of plasma was
incubated with 15 l of beads in 100 l of PBS for 1 h with agitation. Beads were then washed three
times with 200 l of PBS and three times with 200 l of MQ, after which the antibodies were eluted
with 100 l 100 mM formic acid. Eluates were dried for 2 h at 60°C in a vacuum concentrator and
dissolved in 40 l 25 mM ammonium bicarbonate containing 25 ng/l trypsin. Samples were shaken
for 10 min and incubated at 37°C for 17 h.
LC-MS analysis of glycopeptides. The IgG digest was separated and analyzed by an Ultimate 3000
high-performance liquid chromatography (HPLC) system (Dionex Corporation, Sunnyvale, CA) coupled to
a Maxis Impact HD quadrupole time of flight mass spectrometry (QTOF-MS) device (Bruker Daltonics) as
described before (51) and explained in detail in Text S1 in the supplemental material.
Data processing. The raw liquid chromatography-mass spectrometry (LC-MS) data were extracted
and curated using LacyTools v0.0.7.2 as described previously (51, 52); cohort-specific parameters are
provided in the supplemental materials and methods (Text S1). Using the described separation methods,
glycopeptides with the same peptide portion coeluted. This resulted in three glycopeptide clusters: one
for IgG1, one for IgG4, and one for the combination of IgG2 and IgG3. As the study population was mainly
of Caucasian ancestry, the tryptic Fc glycopeptides of IgG2 and -3 were assumed to have identical masses
and could therefore not be distinguished by our profiling method. However, it is possible that for part
of the samples, the IgG3 glycopeptides are coanalyzed with the ones of IgG4, due to the presence of
different IgG3 allotypes (53). All chromatograms were aligned based on the exact mass and the average
retention time of the three most abundant glycoforms of each IgG subclass. After alignment, sum spectra
were created per glycopeptide cluster and then calibrated based on at least five glycopeptides per
cluster with a signal/noise (S/N) ratio higher than 9. For the targeted extraction, analyte lists were created
by manual annotation of summed spectra per biological class (healthy or meningococcal sepsis),
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covering both doubly charged and triply charged species. Compositional assignments were made on the
basis of accurate mass and literature (20, 54). Glycopeptide signals were integrated by including enough
isotopomers to cover at least 95% of the area of the isotopic envelope. Spectra were excluded from
further analysis when the total spectrum intensity was below 10 times the average spectrum intensity of
the blanks. In this way, no spectra were excluded for IgG1, 15 spectra were excluded for IgG2/3, and 29
spectra were excluded for IgG4. Analytes were included in the final data analysis when their average S/N
ratio (calculated per biological class) was above 9, their isotopic pattern did not, on average, deviate
more than 20% from the theoretical pattern, and their average mass error was within 10 ppm. This
resulted in the extraction of 22 IgG1, 15 IgG2/3, and 10 IgG4 glycoforms (Table S2).
Data analysis. The absolute intensities of the extracted glycoforms were total area normalized
per IgG subclass, and derived glycan traits were calculated based on specific glycosylation features
(Table 2 and Table S2). Data quality was evaluated based on the 32 pooled plasma standards that
were randomly included in the cohort. These resulted in highly repeatable profiles showing median
relative standard deviations of 3.6% for the IgG1 glycopeptides, 2.9% for the IgG2/3 glycopeptides,
and 2.4% for the IgG4 glycopeptides (see Fig. S4 in the supplemental material). For 10 patients,
serum, citrate plasma, and EDTA plasma of the same time point were available. For these samples,
the relative intensities of the individual glycoforms were averaged over the different materials and
relative standard deviations were calculated and compared to the standard deviations obtained
from the technical replicates. This revealed in general no higher relative standard deviation over the
different materials than over the technical replicates (Fig. S4). For patients who had different
materials available at the same time point, the data of the samples were averaged. Statistical analysis
was performed using R 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria) and RStudio
0.98.1091 (RStudio, Inc.). First, outliers were removed, which were defined as values outside the 99%
confidence interval per biological group (healthy or meningococcal sepsis). Samples were excluded
from further statistical analysis when two or more of the derived traits per IgG subclass were marked
as outliers. This resulted in the exclusion of one IgG1 sample, one IgG2/3 sample, and two IgG4
samples. The derived glycosylation traits per subclass were tested to correlate with age and the
continuous clinical variables using Spearman’s correlation test. Mann-Whitney U tests were per-
formed to assess glycosylation differences between cases and controls and between patients with
severe and nonsevere disease outcomes. All statistical tests were performed both on the whole data
set and on the subsets of children below the age of 4 years and above the age of 4. The tests for
disease outcome were exclusively performed on the younger age category (below 4 years). The
significance threshold () was adjusted for multiple testing by the Benjamini Hochberg false-
discovery rate (FDR) method, with an FDR of 5%. This resulted in   0.0027 throughout the study.
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